135 related articles for article (PubMed ID: 27994293)
1. Expression IRF/MUM1>25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era.
Sofo-Hafizovic A; Chikha A; Gojak R; Hadzimesic ES
Med Arch; 2016 Oct; 70(5):342-347. PubMed ID: 27994293
[TBL] [Abstract][Full Text] [Related]
2. [Subgrouping and outcome prediction of diffuse large B-cell lymphoma by immunohistochemistry].
Ye ZY; Cao YB; Lin TY; Lin HL
Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):654-9. PubMed ID: 18194597
[TBL] [Abstract][Full Text] [Related]
3. Immunophenotype classification and therapeutic outcomes of Chinese primary gastrointestinal diffuse large B-cell lymphoma.
Zhang Z; Shen Y; Shen D; Ni X
BMC Gastroenterol; 2012 Jun; 12():77. PubMed ID: 22726454
[TBL] [Abstract][Full Text] [Related]
4. Blimp-1 protein and Hans classification on prognosis of diffuse large B-cell lymphoma and their interrelation.
Song Y; Cao Z; Li L; Zhang HT; Zhang X
Chin J Cancer; 2010 Sep; 29(9):781-6. PubMed ID: 20800019
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological Analysis of 320 Cases of Diffuse Large B-cell Lymphoma Using the Hans Classifier.
Ichiki A; Carreras J; Miyaoka M; Kikuti YY; Jibiki T; Tazume K; Watanabe S; Sasao T; Obayashi Y; Onizuka M; Ohmachi K; Yoshiba F; Shirasugi Y; Ogawa Y; Kawada H; Nakamura N; Ando K
J Clin Exp Hematop; 2017; 57(2):54-63. PubMed ID: 29021515
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma.
Colomo L; López-Guillermo A; Perales M; Rives S; Martínez A; Bosch F; Colomer D; Falini B; Montserrat E; Campo E
Blood; 2003 Jan; 101(1):78-84. PubMed ID: 12393466
[TBL] [Abstract][Full Text] [Related]
8. [Nodal versus extranodal diffuse large B-cell lymphoma: comparison of clinicopathologic features, immunophenotype and prognosis].
Lu JB; Li XQ; Zhang PH; Zhou XY; Zhang TM; Li XM; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):470-3. PubMed ID: 17845761
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival.
Haarer CF; Roberts RA; Frutiger YM; Grogan TM; Rimsza LM
Arch Pathol Lab Med; 2006 Dec; 130(12):1819-24. PubMed ID: 17149956
[TBL] [Abstract][Full Text] [Related]
10. CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.
Cozzolino I; Varone V; Picardi M; Baldi C; Memoli D; Ciancia G; Selleri C; De Rosa G; Vetrani A; Zeppa P
Cancer Cytopathol; 2016 Feb; 124(2):135-43. PubMed ID: 26414904
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
[TBL] [Abstract][Full Text] [Related]
12. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of immunohistochemical subtypes in diffuse large B-cell lymphoma and its impact on survival.
Dwivedi A; Mehta A; Solanki P
Indian J Pathol Microbiol; 2015; 58(4):453-8. PubMed ID: 26549066
[TBL] [Abstract][Full Text] [Related]
14. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
15. Immunohistochemical Expression of CD10, BCL6 and MUM1 in Differentiating Diffuse Large B Cell Lymphoma Subtypes.
Bajwa AA; Khadim MT; Din HU; Ali SS; Jamil U; Khan UAS
J Coll Physicians Surg Pak; 2017 Oct; 27(10):621-624. PubMed ID: 29056123
[TBL] [Abstract][Full Text] [Related]
16. [Significance of CD138 in immunohistochemical profiles and its correlation with prognosis in diffuse large B-cell lymphoma].
Zhang HW; Chen ZW; Wang JF; Cheng NL
Zhonghua Zhong Liu Za Zhi; 2011 Feb; 33(2):115-20. PubMed ID: 21575479
[TBL] [Abstract][Full Text] [Related]
17. [Primary gastrointestinal diffuse large B-cell lymphoma: an immunohistochemical and prognostic study of 90 cases].
Lin L; Min M; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):220-6. PubMed ID: 21615994
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of CD10, BCL-6 and multiple myeloma-1 expression in diffuse large B-cell lymphomas in Malaysia.
Peh SC; Gan GG; Lee LK; Eow GI
Pathol Int; 2008 Sep; 58(9):572-9. PubMed ID: 18801072
[TBL] [Abstract][Full Text] [Related]
19. Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients.
Huang Y; Ye S; Cao Y; Li Z; Huang J; Huang H; Cai M; Luo R; Lin T
ScientificWorldJournal; 2012; 2012():897178. PubMed ID: 23213304
[TBL] [Abstract][Full Text] [Related]
20. Incidence of diffuse large B-cell lymphoma of germinal center B-cell origin in whole diffuse large B-cell lymphoma: tissue fluorescence in situ hybridization using t(14;18) compared with immunohistochemistry.
Hirose Y; Masaki Y; Karasawa H; Shimoyama K; Fukushima T; Kawabata H; Ogawa N; Wano Y; Ozaki M
Int J Hematol; 2005 Jan; 81(1):48-57. PubMed ID: 15717689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
